These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 22454413)

  • 1. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
    Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
    J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
    Sorensen PH; Lynch JC; Qualman SJ; Tirabosco R; Lim JF; Maurer HM; Bridge JA; Crist WM; Triche TJ; Barr FG
    J Clin Oncol; 2002 Jun; 20(11):2672-9. PubMed ID: 12039929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization.
    Dumont SN; Lazar AJ; Bridge JA; Benjamin RS; Trent JC
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):213-20. PubMed ID: 22089931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
    Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
    J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas.
    Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M
    Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L
    Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology Group.
    Duan F; Smith LM; Gustafson DM; Zhang C; Dunlevy MJ; Gastier-Foster JM; Barr FG
    Genes Chromosomes Cancer; 2012 Jul; 51(7):662-74. PubMed ID: 22447499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of PAX3/7-FOXO1 fusion status in alveolar rhabdomyosarcoma: Systematic review and meta-analysis.
    Kubo T; Shimose S; Fujimori J; Furuta T; Ochi M
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):46-53. PubMed ID: 26008753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of PAX3/7-FKHR fusion genes and IGF2 gene expression in rhabdomyosarcoma tumors.
    de Souza RR; Oliveira ID; Caran EM; Alves MT; Abib S; Toledo SR
    Growth Horm IGF Res; 2012 Dec; 22(6):245-9. PubMed ID: 23079386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Questionable universal validity of PAX3/FOXO1 fusion gene status as molecular marker for improvement of risk stratification in rhabdomyosarcoma therapy.
    Stegmaier S; Bielack SS; Leuschner I; Klingebiel T; Koscielniak E
    J Clin Oncol; 2012 Nov; 30(32):4039-40; author reply 4040-1. PubMed ID: 23032620
    [No Abstract]   [Full Text] [Related]  

  • 11. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family.
    Sumegi J; Streblow R; Frayer RW; Dal Cin P; Rosenberg A; Meloni-Ehrig A; Bridge JA
    Genes Chromosomes Cancer; 2010 Mar; 49(3):224-36. PubMed ID: 19953635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pax3-fkhr and pax7-fkhr fusion genes impact outcome of alveolar rhabdomyosarcoma in children.
    Kazanowska B; Reich A; Stegmaier S; Békássy AN; Leuschner I; Chybicka A; Koscielniak E
    Fetal Pediatr Pathol; 2007; 26(1):17-31. PubMed ID: 17613043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAX-FOXO1 fusion status in children and adolescents with alveolar rhabdomyosarcoma: Impact on clinical, pathological, and survival features.
    Raze T; Lapouble E; Lacour B; Guissou S; Defachelles AS; Gaspar N; Delattre O; Pierron G; Desandes E
    Pediatr Blood Cancer; 2023 Apr; 70(4):e30228. PubMed ID: 36722003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAX--FKHR fusion genes and AChR-gamma in Chinese patients with rhabdomyosarcoma: diagnosis using formalin-fixed archival tissues.
    Chang B; Pang LJ; Qi Y; Liu CX; Cao Y; Li HA; Hu WH; Jiang JF; Zhang WJ; Li F
    Int J Surg Pathol; 2009 Feb; 17(1):6-15. PubMed ID: 18988640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
    Laé M; Ahn EH; Mercado GE; Chuai S; Edgar M; Pawel BR; Olshen A; Barr FG; Ladanyi M
    J Pathol; 2007 Jun; 212(2):143-51. PubMed ID: 17471488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials.
    Selfe J; Olmos D; Al-Saadi R; Thway K; Chisholm J; Kelsey A; Shipley J
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.
    Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG
    J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
    Ahn EH
    Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
    Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
    Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of fusion gene PAX3/PAX7-FKHR and chromosomal aberration in rhabdomyosarcoma].
    Gao H; Ou YL; Zhang KR; Zhang ZB; Wang WL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Feb; 24(1):42-7. PubMed ID: 17285543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.